NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.
| Revenue (TTM) | $699.19M |
| Gross Profit (TTM) | $533.98M |
| EBITDA | $-136.39M |
| Operating Margin | -5.75% |
| Return on Equity | -43.20% |
| Return on Assets | -9.26% |
| Revenue/Share (TTM) | $6.16 |
| Book Value | $2.90 |
| Price-to-Book | 5.60 |
| Price-to-Sales (TTM) | 2.64 |
| EV/Revenue | 2.411 |
| EV/EBITDA | -6.92 |
| Quarterly Earnings Growth (YoY) | -6.00% |
| Quarterly Revenue Growth (YoY) | 15.60% |
| Shares Outstanding | $116.45M |
| Float | $96.42M |
| % Insiders | 9.96% |
| % Institutions | 90.72% |
Volatility is currently contracting
NovoCure NASDAQ: NVCR outlined its strategy for returning its glioblastoma franchise to growth, expanding launches in pancreatic and lung cancer, and moving toward profitability during the Morgan Stanley Healthcare Conference.
NovoCure Limited (NVCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
NVCR says a cyber incident exposed limited patient and contact data, but devices stayed secure and operations remained fully functional.
The average of price targets set by Wall Street analysts indicates a potential upside of 50.9% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does NovoCure (NVCR) have what it takes to be a top stock pick for momentum investors? Let's find out.
The average of price targets set by Wall Street analysts indicates a potential upside of 53.7% in NovoCure (NVCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Healthcare's defensive demand is strengthening in 2026. BTSG, HRMY, UNH and NVCR stand out on improving earnings outlooks and steady sector momentum.
NovoCure (NVCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The mean of analysts' price targets for NovoCure (NVCR) points to a 46.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Examine the evolution of NovoCure's (NVCR) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on NVCR and any ticker you trade — then tracks every position and per-strategy win rate.
